{name}
{subtitle}
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
city
~66 mi. (Konin, Poland, +144 more cities)
facility
Przychodnia Lekarska KOMED ( Site 2419)
drug
belzutifan, +3 more drugs
drug type
immunotherapy, +1 more type
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
city
~66 mi. (Konin, Poland, +226 more cities)
facility
Przychodnia Lekarska Komed ( Site 0628)
drug
enzalutamide, +1 more drug
drug type
hormone therapy, +1 more type
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
city
~66 mi. (Konin, Poland, +127 more cities)
facility
Przychodnia Lekarska KOMED
drug
cetuximab, +3 more drugs
drug type
chemotherapy, +1 more type
A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010) (MK-7902-010)
city
~66 mi. (Konin, Poland, +127 more cities)
facility
Przychodnia Lekarska Komed ( Site 2500)
drug
lenvatinib, +1 more drug
drug type
immunotherapy, +1 more type
Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)
city
~66 mi. (Konin, Poland, +67 more cities)
facility
Przychodnia Lekarska KOMED ( Site 1202)
drug
carboplatin, +5 more drugs
drug type
chemotherapy, +1 more type
Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002)
city
~66 mi. (Konin, Poland, +76 more cities)
facility
Przychodnia Lekarska KOMED ( Site 1704)
drug
docetaxel, +1 more drug
drug type
chemotherapy, +1 more type
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
city
~68 mi. (Wrocław, Poland, +130 more cities)
facility
Uniwesytecki Szpital Kliniczny we Wroclawiu ( Site 0669)
drug
BCG solution, +1 more drug
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
city
~68 mi. (Wrocław, Poland, +207 more cities)
facility
Dolnoslaskie Centrum Onkologii. ( Site 1820)
biomarker
ER Positive, +1 more biomarker
drug
cyclophosphamide, +6 more drugs
drug type
chemotherapy, +3 more types
Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)
city
~68 mi. (Wrocław, Poland, +159 more cities)
facility
Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego ( Site 1062)
drug
cisplatin, +2 more drugs
drug type
chemotherapy, +1 more type
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)
city
~68 mi. (Wrocław, Poland, +163 more cities)
facility
Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego ( Site 1063)
drug
cystectomy, +2 more drugs
drug type
chemotherapy, +3 more types